Companies · Biotech

Mindstate Design Labs, Inc.Summer 2021Active

SOUTH SAN FRANCISCO · CA, USA · Biotech · refined from filed group “Other · founded 2021 · http://mindstate.design

Diligence memoA one-page analyst read on Mindstate Design Labs, Inc. — recommendation, valuation, rhythm, risks.
$12.7M
Total raised · real
1
Rounds
Latest step-up
Top 14%
Sector rank · raised
Series A
Latest stage · inferred · Fri Nov 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Mindstate Design Labs, Inc. looks fair against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.11× the median modeled value of Series A Biotech companies in 2022–2024 (12 peers) — value vs value, same stage and era.
  • Within the normal band (111% of peer median) for its niche.
Quiet
  • Last raise 20 mo ago; this sector typically re-raises about every 11 months.
  • Slightly overdue versus sector cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotech

Mindstate Design Labs, Inc. is one of 233 Biotech companies tracked from SOUTH SAN FRANCISCO, CA, USA, on record since 2021. By capital raised it ranks in the upper tier (ahead of 87% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst

Clinical-stage AI neuroengineering platform

We're making every therapeutically valuable emotion available on demand in pharmaceutical form. Our Osmanthus platform is an ensemble of AI models that synthesize the world’s largest datasets of psychoactive pharmacology and phenomenology, quantitatively pinpointing the combination of neurotransmitter receptor activity that underlies various emotional as well as cognitive and perceptual states. Our lead program MSD-001 is designed to be rapid-acting and produce heightened emotional and cognitive flexibility without hallucinations. MSD-001 is currently in human trials, and will be the base ingredient for multiple drug combination "emotions in a bottle" such as empathy, awe, clarity, or beauty.

AIBiotechMachine LearningMental Health TechTherapeuticsai/mlpharma
Find Mindstate Design Labs, Inc. online

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
43
Investors (latest)
2020
Year incorporated
2024-11-08
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MSeries A · 2024-11-08 Raised $13M (real) Modeled valuation $56M (est)$13M$56MSeries A2024

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$12.7M · 2024

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$56.2M
Base estimate est.
$13.9M
Conservative case
$111.9M
Upside case
$57.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
1.6 yr
Elapsed time used
1.6 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
Avg between rounds
Capital velocity
1.6 yr
On record since
2024
First round
1
Rounds on file
How it compares to the market

Benchmarked against 233 companies in Biotech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.6× above median
This company$12.7M
Sector median$7.8M
Latest round — vs other Series A rounds in sector (real $, this stage) 2.1× above median
This company$12.7M
Sector median$6.0M
Modeled value — vs sector median (estimate, all stages) 1.0× above median
This company$56.2M
Sector median$56.2M

Raised more than 87% of sector peers (real $). Modeled value above 84% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #5 of 12.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Epsilon3, Inc. · Series A Raised $15.0M · modeled $217.3M (est)Salish Bioscience Inc. · Series A Raised $7.0M · modeled $109.6M (est)HB Biotech, Inc. · Series A Raised $7.8M · modeled $87.8M (est)Acoustic Wave Cell Therapy, Inc. · Series A Raised $20.5M · modeled $85.0M (est)Nurture Genomics, Inc. · Series A Raised $4.3M · modeled $53.5M (est)Talus Bioscience, Inc. · Series A Raised $9.4M · modeled $47.7M (est)Abacus Bioscience Inc. · Series A Raised $4.4M · modeled $46.6M (est)Ark Biotech Inc. · Series A Raised $21.7M · modeled $46.0M (est)Escalante Bioscience, Inc. · Series A Raised $6.7M · modeled $38.1M (est)Zivo Bioscience, Inc. · Series A Raised $14.6M · modeled $34.1M (est)Unite Genomics, Inc. · Series A Raised $7.8M · modeled $14.9M (est)Mindstate Design Labs, Inc. (this company) Raised $12.7M · modeled $56.2M (est)Mindstate Design Labs, Inc.
CompanyStageRaised · realValue · estvs peer med.
Epsilon3, Inc.Series A$15.0M$217.3M4.29×
Salish Bioscience Inc.Series A$7.0M$109.6M2.17×
HB Biotech, Inc.Series A$7.8M$87.8M1.74×
Acoustic Wave Cell Therapy, Inc.Series A$20.5M$85.0M1.68×
Mindstate Design Labs, Inc. this companySeries A$12.7M$56.2M1.11×
Nurture Genomics, Inc.Series A$4.3M$53.5M1.06×
Talus Bioscience, Inc.Series A$9.4M$47.7M0.94×
Abacus Bioscience Inc.Series A$4.4M$46.6M0.92×
Ark Biotech Inc.Series A$21.7M$46.0M0.91×
Escalante Bioscience, Inc.Series A$6.7M$38.1M0.75×
Zivo Bioscience, Inc.Series A$14.6M$34.1M0.67×
Unite Genomics, Inc.Series A$7.8M$14.9M0.29×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$12.7M2024-11-08$57.7M$56.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$12.7M2024-11-08
    • First recorded raise — entered as Series A.
    • 43 investors on this round.
Intelligence
Modeled next raise
$20.3M
Modeled next size est.range $13.2M$32.5M
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Dillan DiNardo2024-11
Rand Hindi2024-11
Thomas Ray2024-11
Registry & provenance

Mindstate Design Labs, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
2046478
SEC CIK
2020
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Tamarind Bio, Inc.BiotechSeries A$13.6M$47.6Msame sector · same stage
Montlake Bioscience Inc.BiotechSeries A$11.3M$410.3Msame sector · same stage
Zivo Bioscience, Inc.BiotechSeries A$14.6M$34.1Msame sector · same stage
Kaneh Bosm Biotechnology Inc.BiotechSeries A$10.9M$90.4Msame sector · same stage
Epsilon3, Inc.BiotechSeries A$15.0M$217.3Msame sector · same stage
Impact Genomics, Inc.BiotechSeries A$10.2M$369.3Msame sector · same stage
Talus Bioscience, Inc.BiotechSeries A$9.4M$47.7Msame sector · same stage
CHD Bioscience, Inc.BiotechSeries A$18.7M$3.3Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Osmind
Platform for breakthrough mental health research and treatment
Healthtech80%
Exin Therapeutics, Inc.
AI drug discovery platform for neurotherapeutics
BiotechnologySeed$8.5M78%
Cognition Therapeutics IncBiotechnologySeries B$65.4M77%
Anthrogen
We're training the next generation of protein foundation models.
Biotech77%
MentalHappy Inc
Group-Therapy Platform for Providers and Health Systems
HealthtechPre-Seed$2.1M77%
Maven Bio
The AI Platform for Life Sciences Intelligence
Biotech77%
Mindset Health
Building AI therapeutics for physical health conditions like IBS.
Pharma77%
Gen1E Lifesciences Inc.
AI platform accelerating therapies for rare & inflammatory diseases.
BiotechnologySeries B$22.5M76%
Frequently asked
How much funding has Mindstate Design Labs, Inc. raised?
Mindstate Design Labs, Inc. has raised approximately $12.7M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Mindstate Design Labs, Inc.'s estimated valuation?
Provath's modeled valuation for Mindstate Design Labs, Inc. is approximately $56.2M (modeled range $13.9M–$111.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Mindstate Design Labs, Inc. at?
Mindstate Design Labs, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Fri Nov 08.
What does Mindstate Design Labs, Inc. do and where is it based?
Mindstate Design Labs, Inc. operates in the Biotech sector, based in SOUTH SAN FRANCISCO, CA, USA. Clinical-stage AI neuroengineering platform
Explore related

See where Mindstate Design Labs, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Mindstate Design Labs, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.